CHMP recommends EU approval of Roche’s Ocrevus for children and adolescents with relapsing multiple sclerosis
Basel, 18 September 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Ocrevus® (ocrelizumab) intravenous (IV) infusion for the treatment of paediatric patients aged 10 years and older with relapsing forms of multiple sclerosis (RMS). The U.S. FDA approved Ocrevus for paediatric RMS patients in May 2026. A final decision from the European Commission is expected in the near future.
Covered in this story
What has happened since
- Roper Technologies is up 6.8% since this was published, 32 days ago.
- Hermès International is up 0.6% since this was published, 32 days ago.
Price move measured from the close nearest publication to the latest quote.
Call it yourself
No calls on $ROG.SW yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Roche Holding →Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.